Skip to main content
Immune repurchases rights to Mylan's leukemia drug Ceplene
6/16/2017

Immune Pharmaceuticals has entered into a contract allowing the firm to reacquire assets for Mylan's Ceplene, or histamine dihydrochloride, a maintenance therapy for acute myeloid leukemia. Immune subsidiary Cytovia would market the drug.

Full Story: